STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
BVXV BIONDVAX PHARMS LIMITED StockScouter® Report
4
StockScouter® Score
BIONDVAX PHARMS LIMITED, a micro cap company in the healthcare sector, is expected to slightly underperform the market over the next six months with slightly higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
- The multi-period measure of relative price change and consistency is above average. Positive/Neutral
Concerns
- The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
- Moving average analysis for BVXV suggests weak price movement over the medium term. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be out of favor, stocks will be , and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
D
C
N/A
C